HC Wainwright Increases ASP Isotopes (NASDAQ:ASPI) Price Target to $5.50

ASP Isotopes (NASDAQ:ASPI) had its target price lifted by research analysts at HC Wainwright from $5.25 to $5.50 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 77.99% from the company’s current price. HC Wainwright also issued estimates for ASP Isotopes’ FY2025 earnings at ($0.07) EPS.

ASP Isotopes Trading Up 1.6 %

ASPI stock opened at $3.09 on Wednesday. The firm has a fifty day moving average price of $3.67 and a 200 day moving average price of $2.39. ASP Isotopes has a fifty-two week low of $0.28 and a fifty-two week high of $4.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.85 and a current ratio of 1.85. The firm has a market cap of $151.17 million, a PE ratio of -6.31 and a beta of 5.03.

Insider Activity at ASP Isotopes

In other news, Director Robert John Andrew Ryan acquired 15,596 shares of the company’s stock in a transaction on Monday, January 29th. The stock was bought at an average cost of $2.35 per share, with a total value of $36,650.60. Following the completion of the purchase, the director now directly owns 537,055 shares of the company’s stock, valued at $1,262,079.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 26.30% of the stock is currently owned by insiders.

Institutional Trading of ASP Isotopes

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of ASP Isotopes during the fourth quarter valued at $26,000. Millennium Management LLC purchased a new stake in shares of ASP Isotopes during the fourth quarter valued at $49,000. HTLF Bank bought a new stake in shares of ASP Isotopes in the fourth quarter valued at about $141,000. Citadel Advisors LLC bought a new stake in shares of ASP Isotopes in the fourth quarter valued at about $187,000. Finally, Rathbones Group PLC bought a new stake in shares of ASP Isotopes in the fourth quarter valued at about $272,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.